Bipolar drug firm agrees deal to keep supplying health service with Priadel – The Times

A drug firm accused by the pinnacle of the NHS in England of attempting to “price-gouge” taxpayers has backed down and agreed to maintain promoting a bipolar drug after hanging a deal permitting modest worth rises.

Important Pharma had deliberate to withdraw the main model of lithium carbonate from the market in a transfer that might have price the NHS as a lot as £15 million a yr.

The Occasions revealed this yr that the withdrawal of Priadel would have pushed 50,000 sufferers who depend on it to the choice model Camcolit, which Important Pharma additionally owns, and which the corporate has beforehand elevated in worth by as much as 2,600 per cent.

After an outcry from docs and medical our bodies who warned that forcing bipolar

Leave a Reply

Your email address will not be published. Required fields are marked *